{"id":"rimegepant-pf-07899801","brandName":"Rimegepant (PF-07899801)","genericName":"rimegepant-pf-07899801","companyId":"pfizer","companyName":"Pfizer Inc.","phase":"phase_3","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":5,"visitCount":8,"mechanism":{"target":"CALCRL","drugClass":"CGRP receptor antagonist","explanation":"Rimegepant works by blocking the CGRP receptor, which is involved in the dilation of blood vessels and transmission of pain signals during migraines. By inhibiting this pathway, it helps reduce the frequency and severity of migraine attacks.","oneSentence":"Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine headaches."},"administration":{},"safety":{},"trials":[],"indications":{"approved":[],"pipeline":[],"offLabel":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:37:09.871343+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}